A fundamental part of ESCAPE is our randomised controlled trial led by ESCAPE project partner Professor Christoph Herrmann-Lingen at Universitätsmedizin Göttingen (Germany).

Focusing on patients with chronic heart failure, psychological distress and at least two other physical co-morbidities, the trial will compare the outcomes of ESCAPE’s new, blended collaborative-care approach with current patient care. Findings will determine which approach leads to the best health-related quality of life for patients.

Thanks to the hard work of the consortium, ESCAPE’s clinical trial is running in our 10 project sites, across five countries! The first patient was enrolled on April 1st 2022, and now over 200 patients have been randomised to the intervention study. Recruitment will likely be completed in late 2024, with final results being available in 2025.